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Introduction
Free fatty acid receptors 1 (FFA1, previously known as GPR40) and 4 (FFA4, previously known as GPR120) are modulators of nutrient-stimulated glucose regulation and are therefore, therapeutic targets for the treatment of type 2 diabetes mellitus (T2DM). FFA1 selective agonists have been shown to cause glucose-sensitive insulin secretion (Tsujihata et al., 2011) . FFA1 and FFA4 were deorphanized in 2003 and 2005 respectively, as receptors for medium to long chain unsaturated fatty acids (Itoh et al., 2003; Hirasawa et al., 2005) . As endogenous free fatty acids (FFAs) often activate more than one receptor type (Kostenis, 2004) and are metabolized to act as intracellular signalling molecules (Warnotte et al., 1994) , they have limited utility as selective tools to establish the pharmacology and functional significance of specific FFA receptors. The recent discovery of selective, small molecule agonists for FFA1 and FFA4 receptors therefore, provided a pharmacological advantage over non-selective endogenous FFAs and this study set out to utilize some of these new tool compounds to investigate FFA1 and FFA4 receptor signalling specifically.
Apart from FFA1 and FFA4 receptors there are alternative FFA receptors in the gastrointestinal (GI) tract including FFA2 (formerly GPR43), FFA3 (GPR41) receptors and the acylethanolamide receptor, GPR119, all of which are selectively expressed in enteroendocrine L cells together with FFA1 and FFA4 receptors (Hirasawa et al., 2005; Karaki et al., 2006; Overton et al., 2006; Edfalk et al., 2008) . Both FFA1 (Briscoe et al., 2003) and FFA4 receptors have the capacity to couple to Gα q/11 , activate phospholipase C and elevate Ca 2+ levels, leading to the release of L cell peptide hormones. Colonic L cells contain peptide YY (PYY), the incretin glucagon-like peptide 1 (GLP-1) plus GLP-2 and oxyntomodulin (Egerod et al., 2012; Habib et al., 2013; Cho et al., 2014) . Additionally, small intestine L cells express neurotensin and cholecystokinin (CCK) (Egerod et al., 2012 , Habib et al., 2013 . In this study, we utilized the descending colon because this colonic region exhibits a greater degree of PYY-Y 1 receptor signalling compared with the ascending colon (Cox et al., 2001) and L cell density is greater in the distal colon in mouse (Arantes and Nogueira, 1997) and human (Adrian et al., 1985) . GLP-1 slows gastric emptying and enhances satiety (Little et al., 2006) , while PYY is a well-known mediator of the ileal and colonic brakes (Lin et al., 1996) and a major satiety-inducing agent together with its product, PYY (Batterham et al., 2002) . PYY is also a significant inhibitor of intestinal epithelial ion transport, and we have previously utilized this activity to monitor the acute endogenous peptide functionality following L cellspecific stimulation with GPR119 agonists (Cox et al., 2010; Patel et al., 2014) or other L cell-mediated mechanisms (Joshi et al., 2013; Panaro et al., 2014) . In mouse and human distal colon, local mucosal PYY antisecretory actions are predominantly mediated via epithelial Y 1 receptors with a smaller component of submucosal neuron Y 2 receptor activity (Tough et al., 2006; Tough et al., 2011) that together underpin endogenous PYY paracrine responses. FFA1 and FFA4 receptors are also potential nutrient-sensing receptors in L cells and are therefore, possible targets for the treatment of T2DM and obesity (Engelstoft et al., 2008) .
The FFA1 agonist TAK-875 (Negoro et al., 2010) , which in phase II trials lowered blood glucose without apparently increasing GLP-1 levels, was shown to signal via Gα q/11 alone, in a manner similar to the proposed endogenous agonist, α-linolenic acid. In type II diabetic rats, TAK-875 improved glucose tolerance and enhanced glucose-dependent insulin secretion (Tsujihata et al., 2011) . Despite the liver toxicity concerns of TAK-875, it significantly improved glycaemic control in diabetic Japanese patients in a phase III study (Kaku et al., 2015) . JTT, a novel selective FFA1-targeted agonist (from patent number WO 2009/054479), TAK-875 and the commercially available FFA1 agonist TUG424 (Christiansen et al., 2008) were selected to assess the pharmacology of FFA1 receptors in this study.
The FFA4 receptor is also found abundantly in gastric inhibitory peptide (GIP)-containing K cells of the small intestine, gastric somatostatin (SST)-containing D cells and gastric ghrelin-containing A cells (Ito et al., 2009; Parker et al., 2009; Engelstoft et al., 2013; Egerod et al., 2015) . The functional roles of FFA4 receptors include enhanced insulin secretion, GLP-1 secretion (Halder et al., 2013) , reduced gastric emptying (Little et al., 2006) and anti-inflammatory effects (Oh et al., 2010) . FFA4 knockout mice exhibited a significantly reduced L cell GLP-1 secretion (Xiong et al., 2013) and K cell GIP secretion (Iwasaki et al., 2015) , indicating that signalling via the FFA4 receptor in wild-type tissues can cause incretin peptide release. The novel selective agonists selected for this study, AZ423 (compound 34; McCoull et al., 2017) and Metabolex-36 (Ma et al., 2010) , show 100-fold selectivity for murine FFA4 compared with FFA1 (Stone et al., 2014) . Furthermore, AZ423 and Metabolex-36 have exhibited a reduction in blood glucose excursion in an oral glucose tolerance test (Halder et al., 2013; McCoull et al., 2017) . Additionally, the selected commercially available FFA4 agonist, TUG891, is selective for murine and human FFA4 receptors (Hudson et al., 2013) . Whether intestinal FFA4 agonism resembles FFA1 activities and is also glucose-sensitive in enteroendocrine L cells has yet to be determined.
As few functional studies have been performed in native preparations containing L cells, one aim of this study was to determine the potencies and efficacies of the commercially available agonists (TUG424 and TUG891) compared with the non-selective FFA1 and FFA4 agonist GW9508 and importantly the novel selective agonists JTT, TAK-875, AZ423 and Metabolex-36 in mouse colon. We also assessed the selectivity of the FFA1-preferring antagonist GW1100 (Briscoe et al., 2006) comparing it with ANT825, a selective FFA1 antagonist (referred to as compound 39 in Waring et al., 2015) and determined their relative abilities to reveal tonic FFA1 activity. We also determined the involvement of endogenous PYY in these responses in colonic mucosae by blocking peptide activity pharmacologically. Finally, the effects of FFA1 and FFA4 agonism upon colonic motility in vitro and in vivo were established. and had free access to standard chow (Rat and Mouse No 3 breeding diet, Special Diets Services, Braintree, UK) and water ad libitum. We used mice because the Y 1 , Y 2 and Y 4 receptor localization in the GI tract is the same in this species as in the human colon (Cox and Tough, 2002; Tough et al., 2011) . Mice were housed in open top conventional cages with Lignocel poplar bedding material along with appropriate environmental enrichment. A maximum of five mice were housed in a single cage. Housing rooms were maintained at 20-24°C, humidity 55 ± 10% and 12/12 h light and dark cycle. All animal care and experimental procedures complied with the Animals (Scientific procedures) Act 1986 and were approved by the UK Home Office (licence number: PPL70/ 7887). Also, animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Mice were killed by cervical dislocation, and the whole colon was dissected (noting proximal and distal ends) and placed in fresh Krebs-Henseleit (KH) solution of the following composition (in mM); NaCl 118, KCl 4.7, NaHCO 3 25, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.5 and D-glucose 11.1. Mucosae from the descending colon were prepared by removing the overlying smooth muscle layers and associated myenteric plexi by micro-dissection. Mucosal lengths were cut into four to six adjacent pieces, each of which was mounted between two halves of an Ussing chamber (WPI UK, Hitchin, Herts, UK) (exposed area, 0.14 cm 2 ), voltage-clamped at 0 mV (DVC1000 and amplifiers; WPI UK, Hitchin, Herts, UK) and equilibrated in oxygenated KH (95% O 2 /5% CO 2 , at 37°C) for 15 min. Drug additions were made to either the basolateral (bl) or apical (ap) reservoirs and changes in short-circuit current (I sc ) were measured continuously.
Sidedness, potency and efficacy of the FFA1 and FFA4 compounds Mucosae were pretreated with vasoactive intestinal polypeptide (VIP, 30 nM, bl) to provide a degree of vectorial epithelial ion secretion upon which subsequent antisecretory signalling is more readily observed (as optimized previously; Tough et al., 2006; Cox et al., 2010) . Once VIP responses had reached a maximum, an FFA1 or FFA4 agonist [TUG424 (300 nM), TUG891 (300 nM) or GW9508 (10 μM)] was added to either reservoir as indicated, to determine the approximate sidedness of the FFA1 and FFA4 receptor-mediated responses. Single additions of apical FFA1 or FFA4 agonists were used to construct concentration-response curves and calculate single EC 50 values with GraphPad Prism v6.0. Changes in I sc to certain FFA1 agonists (TAK-875, JTT and GW9508) and FFA4 agonists (Metabolex-36 and AZ423) were biphasic; the first component (1°) being a transient increase in I sc (within 5 min) followed by a longer-lasting reduction in I sc (the second component, 2°) was extrapolated from the waning VIP signal and reached its maximum within 10-15 min of FFA drug addition. When the biphasic changes in I sc were observed, the 1°and 2°components were analysed separately. To investigate whether there was a neuronal component to FFA1 (TAK-875, 200 nM) and FFA4 (Metabolex-36, 100 nM) signalling, mucosae were pretreated with the neurotoxin, tetrodotoxin (TTX, 100 nM, bl) or vehicle (H 2 O) for 15 min, followed by VIP and subsequently the FFA1 or FFA4 agonist. The responses to TAK-875 and Metabolex-36 were monitored for 20 min and finally PYY (10 nM, bl) was added as an internal control. Changes in I sc to each drug or peptide were pooled and converted to μA·cm À2 .
Establishing the selectivity of FFA1 and FFA4 agonism using antagonists
In order to establish an IC 50 of the FFA1 antagonist, ANT825, basal I sc levels were allowed to stabilize before the addition of various single concentrations (1 nM-10 μM) of the FFA1 antagonist. After 10-15 min, VIP was added, followed by the selected FFA1 agonist JTT (300 nM), and consequent reductions in I sc were recorded and converted to μA·cm À2 .
PYY (10 nM) was added finally as an internal control. The antagonist concentration (10 μM, ANT825) that abolished JTT responses was used in subsequent selectivity studies. Blockade of the FFA1 agonists (TUG424, GW9508, JTT and TAK-875) was confirmed using the antagonists GW1100 (10 μM) (Briscoe et al., 2006) or ANT825 (10 μM). Here, mucosae were pretreated apically for 10 min with the appropriate vehicle (0.1% DMSO) or the chosen FFA1 antagonist prior to VIP addition. TUG424 (100 nM) and GW9508 (1 μM) were the FFA1 agonists tested initially, followed by TAK-875 (200 nM) and JTT (300 nM), while TUG891 (100 nM), Metabolex-36 (100 nM) and AZ423 (100 nM) were used to preferentially activate FFA4 receptors unless otherwise stated. Finally, PYY (10 nM) was added as an internal control. ANT825 was chosen as the preferred FFA1 antagonist in further studies.
Y 1 and Y 2 receptor antagonist (BIBO3304 and BIIE0246) studies Tissues were pretreated with previously optimized concentrations of the Y 1 antagonist BIBO3304 (BIBO, 300 nM, bl) or the Y 2 antagonist, BIIE0246 (BIIE, 1 μM, bl) or both, versus their respective DMSO (0.003-0.1%) controls. After 10-15 min VIP was added, and once this response had stabilized, a single apical concentration of the FFA1 or FFA4 agonists was added and the consequent reduction in I sc was converted to μA·cm À2 . PYY and the α 2 -adrenoceptor agonist, UK14 304 (1 μM) were used as internal controls.
Mucosal glucose-sensitivity studies
Excised whole colon was placed in fresh glucose-free KH with the following composition (in mM); NaCl 118, KCl 4.7, NaHCO 3 25, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.5 and D-mannitol 11.1. Mucosae were dissected as described above, placed in Ussing chambers and were bathed in KH containing glucose on both sides or with glucose replaced with mannitol (at 11.1 mM) on the ap side only. When investigating FFA1 and FFA4 agonism in the presence of lower or higher glucose; the glucose concentration was altered (either 5 or 25 mM in KH) on ap and bl sides simultaneously. Mucosal basal I sc levels were allowed to stabilize before the addition of VIP, and once stabilized, a single apical addition of the FFA1 or FFA4 agonists was added and consequent reductions in I sc were recorded and converted to μA·cm À2 . Phloridzin (Phlor; 50 μM, ap), the sodium-glucose co-transporter 1 (SGLT1) inhibitor, was used to block apically located SGLT1, and this electrogenic response should be lost when mannitol replaced apical glucose.
Faecal pellet propulsion in vitro
The colon (from the caeco-colonic junction to the rectum) was excised, photographed (t = 0 min) and bathed in KH at 37°C with either vehicle (0.1% DMSO) or agonist (300 nM TUG424, TUG891, TAK-875 or Metabolex-36) as indicated. After 20 min (t = 20 min), each colon length was re-photographed and the distance travelled by the remaining pellets was measured from the rectum, as described previously (Tough et al., 2011) . The effects on transit of the agonists were compared in the absence and presence of the FFA1 antagonist, GW1100 (10 μM).
In these experiments, the colon was bathed in vehicle (0.1% DMSO) or antagonist, photographed at 20 min and then bathed in KH containing the agonist of choice for 20 min.
The colon was re-photographed at t = 40 min. The pellet movement was measured as mean distance travelled relative to the total colonic length and was used to calculate the % colonic transit.
Colonic bead excretion in vivo
Mice were acclimatized to handling 3 days prior to experimentation and were fasted 16 h prior to testing, although water was provided ad libitum. Plasma glucose before the fast was 10.5 ± 0.9 mmol·L À1 (mean ± 1 SEM, n = 9) and 4.8 ± 0.3 mmol·L À1 after fasting (n = 9). Distal colonic propulsion was measured according to the methods described by Forbes et al. (2012) . One hour after administration of vehicle, or drug (FFA1 agonist, TAK-875; FFA4 agonist, Metabolex-36, FFA1 antagonist, ANT825) or the positive control [loperamide hydrochloride (HCl) by oral gavage or i.p. injection], mice were placed under 4-5% isoflurane anaesthesia (Isoflurane-VET; Merial Animal Health Ltd, Harlow, UK) and a 2 mm bead was inserted 2 cm intrarectally into the distal colon using blunt tubing (Portex, 1.7 × 0.4 mm). The mice were subsequently placed into a grid bottom cage, monitored and the time to bead expulsion was measured.
Once the bead was excreted, the mouse was killed by cervical dislocation. All drugs were suspended in their respective vehicles and sonicated for 30 min.
Upper GI transit in vivo
Mice were acclimatized to handling 3 days prior to experimentation and were fasted for 16 h prior to testing. TAK875, Metabolex-36, ANT825, their respective vehicles or loperamide HCl was administered via i.p. injection, 60 min prior to testing. In the experiments that used the somatostatin SST 2 receptor antagonist, CYN 154806, mice were pretreated with the antagonist (3 mg·kg À1 ) or saline for 15 min, prior to Metabolex-36 (50 mg·kg À1 , i.p.). A charcoal meal [10% plant charcoal in 5% gum acacia (Tough et al., 2011) ] was given by intragastric gavage and 30 min later, the animal was killed by cervical dislocation and the small intestine was isolated from the pyloric to ileocecal junctions. Upper GI transit (UGIT), encompassing gastric emptying and small intestinal motility was determined as previously described (Forbes et al., 2012) .
Statistical analysis
Pooled responses (as μA·cm À2 ) are expressed as mean ± SEM from the numbers of observations shown, using GraphPad Prism version 6.0 (GraphPad Prism Inc., La Jolla, CA, USA).
Single comparisons between groups of data were analysed by unpaired, two-tailed Student's t-test or one-way ANOVA for multiple comparisons with post hoc Dunnett's test. Post hoc tests were run only when F achieved P < 0.05 and there was no significant variance inhomogeneity. P < 0.05 was considered statistically significant. Mice (males and females) were randomized in this study. Additionally, drug treatments added to each mucosal preparation were randomized using the Latin square design technique. Furthermore, vehicle and drug treatments were alternated in the in vivo studies for each cohort. However, explicit blinding was not performed; each replicate was compared with one another and the drugpretreated replicates. Any discrepancies between n number cohorts were due to the loss of a single mucosal preparation from a single animal in vitro, or a value was removed when it was more than two standard deviations from the mean in vitro and in vivo. The data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Materials
FFA1 (JTT and TAK-875) and FFA4 agonists (AZ423 and Metabolex-36) and the FFA1 antagonist (ANT825) were obtained from AstraZeneca (Gothenburg, Sweden). Stock solutions of drugs were dissolved in neat DMSO (at 10 À2 M or 10 À3 M). Initial 1:10 dilutions were in neat DMSO, and subsequent serial dilutions were in distilled water (excluding the FFA1 agonist, TAK-875 and the FFA4 agonist, AZ423, where all serial dilutions were performed in distilled water).
acid, ethyl ester) and loperamide HCl were from Cambridge Bioscience (Cambridge, UK). VIP and PYY were purchased from Cambridge Bioscience (Cambridge, UK) and TTX from Abcam (Cambridge, UK). VIP, PYY and TTX were dissolved in distilled water. All peptide stocks were stored at À20°C until required and underwent a single freeze-thaw cycle. Phlor (1-[2-(β-Dglucopyranosyloxy)-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl]-1-propanone) was purchased from Sigma-Aldrich (Dorset, UK), and it too was dissolved in distilled water. The following in vivo vehicles were all suspended in warm saline, methylcellulose and polyvinylpyrrolidinone (PVP) from Sigma-Aldrich (Dorset, UK), sodium dodecyl sulfate (SDS) from VWR International (Leicestershire, UK), hydroxylpropyl methylcellulose (HPMC) from Alfa Aesar (Lancashire, UK) and Tween-80 from Boston BioProducts (Ashland, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
The sidedness, potency and efficacy of FFA1 and FFA4 agonists in descending colon mucosa First, basal resistance and I sc levels after stabilization of the colonic mucosae were within ranges published previously ( Figure 1A ) (Tough et al., 2011) . The activity of the nonselective FFA1 and FFA4 agonist, GW9508 ( Figure 1B) , as well as the TUG compounds added apically or basolaterally induced a biphasic change in I sc . When the reductions in I sc were compared, there were no significant differences between the response sizes to each agonist added to either side ( Figure 1C ). The more selective FFA1 agonists, TAK-875 and JTT and FFA4 agonists, Metabolex-36 and AZ423 were added apically and induced a biphasic I sc response. The rapid first I sc component was attributed to the vehicle, 0.1% DMSO (3.0 ± 1.1 μA·cm À2 , n = 12) when compared with the same component for JTT (1.7 ± 0.9 μA·cm
À2
, n = 5) and Metabolex-36 (3.2 ± 1.7 μA·cm
, n = 4) or 0.01% DMSO (3.0 ± 1.1 μA·cm À2 , n = 6) when compared with TAK-875 (2.5 ± 1.3 μA·cm
, n = 6) and AZ423 (4.6 ± 1.4 μA·cm À2 , n = 6). Only the later reductions in I sc to varying concentrations of each FFA1 and FFA4 agonists are shown in Figure 1D -F. To determine whether the FFA1 and FFA4 responses were neuronal, we pretreated the mucosae with TTX (100 nM, bl). The responses to TAK-875 (À11.2 ± 2.0 μA·cm À2 , n = 5) and Metabolex-36 (À8.3 ± 2.3 μA·cm
, n = 5) were unaffected by TTX compared to their DMSO controls (À7.5 ± 1.8 μA·cm À2 and
, respectively n = 5), indicating that FFA1 and FFA4 receptor-mediated responses are most likely epithelial in origin and are not mediated by TTX-sensitive neurons.
The reductions in I sc to each agonist were concentrationdependent, with TUG424 and TUG891 being similarly potent, approximate EC 50 values were 57.1 nM (24.7-131.8 nM) and 62.5 nM (24.1-162.3 nM) respectively ( Figure 1D ). GW9508 was less potent with an EC 50 value of 354.8 nM (191.6-656.8 nM) and appeared to be slightly more efficacious; however, this was not significantly different from the TUG agonists ( Figure 1D ) or the selective FFA1 or FFA4 agonists. JTT was more potent [EC 50 of 20.7 nM (12.7-34.0 nM)] than TAK-875 [EC 50 of 67.6 nM (30.6-149.4 nM)], and they exhibited similar efficacy ( Figure 1E) . Furthermore, the FFA4 agonist Metabolex-36 [EC 50 of 15.4 nM (7.9-30.4 nM)] and AZ423 [EC 50 of 17.3 nM (3.6-83.8 nM)] were similarly potent and efficacious ( Figure 1F ). In comparison to the selective FFA1 and FFA4 agonists, GW9508 appeared to be a dual agonist.
GW1100 and ANT825 each inhibit agonist-induced FFA1 receptor-mediated responses in the descending colon
The FFA1 antagonists, GW1100 and ANT825 alone revealed a similar degree of FFA1 tonic activity under basal conditions in the distal colon (Figure 2A ). ANT825 inhibited JTT responses competitively ( Figure 2B) , with an IC 50 of 219 nM. Optimal blocking concentrations of each FFA1 antagonist, GW1100 or ANT825 revealed the selectivity of TUG424 and GW9508 for the FFA1 receptor. TUG891 responses were not affected by either FFA1 antagonist. Additionally, only part of the GW9508 response was reduced in the presence of ANT825 or GW1100 ( Figure 2C ). The FFA1 selective agonists (TAK-875 and JTT) were significantly inhibited by ANT825, whereas the FFA4 selective agonists Metabolex-36 and AZ423 responses were unaffected ( Figure 2D ). Figure 3A ) similar to that observed in the mouse colon previously (Hyland et al., 2003; Tough et al., 2011) . FFA1 responses to JTT ( Figure 3B ) and TAK-875 ( Figure 3C) were abolished by the Y 1 antagonist, indicating that PYY-Y 1 signalling predominantly mediates FFA1 responses. The FFA1 responses in the presence of the Y 2 antagonist were slightly reduced, suggestive of a minor role for Y 2 receptors as seen previously (Tough et al., 2011) . Notably, there was no influence of the I sc level at the time of adding the FFA1 agonist on subsequent FFA1 efficacy. Taken together, these observations confirm selective Y 1 -mediation of FFA1 responses. Subsequent exogenous PYY responses were also abolished by the Y 1 , but not by the Y 2 antagonist alone, while the combination abolished PYY activity ( Figure 3D ). The responses to FFA4 agonists AZ423 ( Figure 3E ) and Metabolex-36 ( Figure 3F 
FFA1 and FFA4 receptor-mediated responses are glucose-sensitive in the descending colon mucosa
In order to establish the glucose-sensitivity of FFA signalling in mucosal preparations, the responses to the FFA1 and FFA4 agonists were compared in the presence or absence of apical glucose. Mannitol replacement of apical glucose abolished the FFA1 responses ( Figure 4A , B) and inhibited FFA4 activity ( Figure 4C , D) compared to vehicle. Internal controls using Phlor (added apically) decreased the I sc , but as expected only in the presence of glucose (because SGLT1 requires glucose to function and is targeted apically). Thus, FFA1 and FFA4 receptors can be activated in a glucosesensitive manner. In contrast, PYY responses were not glucose-sensitive (Figure 4A-D) . Furthermore, TAK-875 and Metabolex-36 responses were not affected when the glucose concentration (ap + bl) was varied to represent a hypoglycaemic (5.0 mM) or hyperglycaemic (25.0 mM) environment ( Figure 4E ).
Caeco-colonic transit is inhibited by FFA1 and FFA4 agonists
Since FFA1 and FFA4 mucosal responses in the colon were mediated by PYY and this endogenous peptide is known additions of GW9508 (n = 5), TUG424 (n = 5) or TUG891 (n = 5). The 1°responses were recorded within 0-5 min of agonist addition (and were due to vehicle), whereas 2°reductions in I sc occurred within 10-15 min. Concentration-response curves for the 2°effects of TUG424 [n = 5 for all concentrations, except 300 nM (n = 6)] and TUG891 (n = 5) compared with GW9508 (n = 5) shown in grey in (D); for JTT (n = 5) and TAK-875 [10 nM (n = 5), 30 nM (n = 5), 100 nM (n = 6), 300 nM (n = 5), 1 μM (n = 7) and 3 μM (n = 8)] in (E); and AZ423 (n = 5) and Metabolex-36 (n = 5) in (F). Bars and points are the means ± SEM. to slow colonic transit (Tough et al., 2011) , we next assessed whether the FFA1 and FFA4 agonists reduced transit at single optimal concentrations (300 nM; Figure 5A ). In isolated colons, TUG424, TUG891, TAK-875 and Metabolex-36 significantly decreased transit in comparison to vehicle-treated (DMSO, 0.1%) controls.
Since GW1100 (10 μM) inhibited FFA1 responses in colonic mucosa, we set out to determine whether GW1100 alone could increase basal faecal transit and reverse the effect of the FFA1 agonist on colonic transit, in vitro. Figure 5B shows that GW1100 alone significantly increased basal colonic transit, again indicating endogenous FFA1 inhibitory tone. After 20 min pretreatment with the FFA1 antagonist, GW1100, the effect of TUG424 and TUG891 was assessed in the presence and absence of GW1100. In the presence of GW1100, the inhibitory effect on colonic transit of TUG424 was reversed, but GW1100 had no effect on TUG891 (FFA4) activity, showing FFA1 selectivity ( Figure 5B ).
Colonic bead propulsion is slowed by Metabolex-36 not TAK875 or ANT825 in vivo
As the FFA1 and FFA4 agonists (TAK-875 and Metabolex-36, respectively) slowed transit in isolated colons in vitro, we assessed the ability of these agonists and loperamide HCl to slow colonic transit in vivo, comparing oral administration versus i.p. injection. Additionally, we investigated whether ANT825 had the potential to reveal FFA1 tone in vivo. Oral administration of the positive control, loperamide HCl, significantly slowed transit compared to its vehicle control. Two doses of Metabolex-36 were assessed orally; the lower dose had no effect on transit whereas the higher dose significantly slowed transit. Furthermore, oral gavage of TAK-875 and ANT825 had no effect on colonic transit ( Figure 6A ). Both loperamide HCl and Metabolex-36 significantly slowed colonic transit when given via i.p. injection, whereas TAK-875 and ANT825 had no effect ( Figure 6B ). As i.p. injection of loperamide HCl slowed transit more efficiently in comparison to oral gavage, we used this route of administration for each drug in the subsequent in vivo studies.
Upper GI transit is increased by Metabolex-36 in vivo
Here, we investigated whether the FFA agonists (i.p.) and loperamide HCl could slow intestinal transit and additionally whether ANT825 could increase intestinal transit (revealing FFA1 tone), after mice were given a charcoal meal (as described in the Methods). The positive control, loperamide HCl significantly slowed GI transit as expected compared to its vehicle control. Unexpectedly, Metabolex-36 significantly increased intestinal transit whereas TAK-875 and ANT825 had no effect (Figure 7 ).
SST 2 receptor inhibition has no effect on Metabolex-36-induced UGITeffect in vivo
As Metabolex-36 increased UGIT in vivo, we investigated whether this was due to an inhibitory FFA4 effect (via a Gα imediated mechanism) on somatostatin-containing D cells in the GI tract. This attenuation would result in disinhibition and ultimately a pro-motile effect, as somatostatin is a known inhibitor of GI motility. Mice were pretreated with the SST 2 antagonist, CYN 154806 or saline before the effect of Metabolex-36 was tested. CYN 154806 + Metabolex-36 had no effect on the UGIT of the charcoal meal, in comparison to mice pretreated with saline ( Figure 8 ).
Discussion
The improved selectivity of FFA1 and FFA4 agonists versus commercially available agonists FFA1 and FFA4 agonism was independent of the surface of administration and the time dependence of I sc changes was similar, suggesting that these receptors are located on both the apical and basolateral surfaces. However, it should be noted that all the drugs used were lipid soluble, requiring DMSO as a vehicle; therefore, drugs added on the apical surface could activate FFA receptors on the basolateral side and vice versa. Interestingly, Christensen et al. (2015) showed preferential but not exclusive vascular (basolateral) FFA1-induced GLP-1 secretion using endogenous and synthetic agonists, in rat small intestine. We utilized apical administration, and the reductions in I sc we observed occurred within the same time frame as other apically located L cell Gα qcoupled receptors, some activated by water-soluble compounds (Joshi et al., 2013; Forbes et al., 2015; Alamshah et al., 2016) , thus indicating apical receptors. GW9508 is reported to act via FFA1 and FFA4 receptors with 100× higher affinity for FFA1 than FFA4 (Briscoe et al., 2006) . GW9508 is a dual agonist at the FFA1 and FFA4 Figure 4 Glucose sensitivity of FFA1 and FFA4 receptor-mediated agonism in the descending colon. Glucose sensitivity of apical FFA1 agonists, JTT (300 nM, n = 5) in (A) and TAK-875 (200 nM, n = 5) in (B), and apical FFA4 agonists, AZ423 (100 nM, n = 5) in (C) and Metabolex-36 (100 nM, n = 5) in (D), in the presence (black bars) and absence (white bars) of 11.1 mM glucose. Control mucosae were bathed in glucose both sides, whereas mannitol (+mann, 11.1 mM) replaced glucose apically only. Phloridzin (Phlor, 50 μM, apically only) and PYY (10 nM) responses are also shown. (E) Antisecretory responses to TAK-875 (200 nM, n = 5) and Metabolex-36 (100 nM, n = 5) in the presence of apical and basolateral (ap + bl) 5.0 mM glucose or 25.0 mM glucose. Bars represent the mean-1SEM. Statistical differences between agonist or Phlor responses in the presence or absence of glucose are shown as follows; *P < 0.05 (Student's t-test).
receptors, and this may explain its slightly greater efficacy than more selective agonists we used. We found that the selective FFA1 and FFA4 agonists exhibited a similar potency, and were more potent than GW9508. Both FFA4 agonists, Metabolex-36 and AZ423 have >100-fold higher selectivity for FFA4 in comparison to FFA1. This phenomenon of higher potency but lower efficacy has been observed previously with a GPR119 agonist, PSN-GPR119 (Patel et al., 2014) , and may indicate acute receptor desensitization.
FFA1 agonists are preferentially Gα q/11 linked, and recent evidence suggests that 'Gα q/11 -only' FFA1 agonists (e.g. TAK-875) stimulate the release of incretin hormones, GLP-1 and GIP, with reduced efficacy compared to FFA1 agonists that signal via Gα q/11 and Gα s pathways (Hauge et al., 2015) . Our FFA1 agonists appear to be Gα q/11 -coupled preferentially as
Figure 5
Colonic transit is slowed by FFA1 and FFA4 agonists in isolated colons in vitro. Colonic transit is slowed by 300 nM TUG424 (n = 6), TAK-875 (n = 6), TUG891 (n = 6) and Metabolex-36 (Met-36, n = 6) in (A) at t = 20 min. (B) The effects of FFA1 antagonist GW1100 (10 μM) are compared on basal faecal transit at t = 20 min and on subsequent inhibition of transit following 20 min treatment with TUG424 or TUG891 at t = 40 min (n = 5). Each bar represents the mean+1SEM. Statistically significant differences from controls were *P < 0.05 (Student's t-test) and + P < 0.05 (one-way ANOVA with Dunnett's post hoc test).
Figure 6
The effect of oral gavage (A) versus i.p. injection (B) of FFA ligands and loperamide HCl on colonic bead expulsion in vivo. The effect on colonic bead expulsion [expressed as time until bead expelled (min)] after oral gavage or i.p. injection of loperamide HCl (10 mg·kg À1 , red bar, n = 11) compared with its vehicle control, 0.5% methylcellulose (blue bar, n = 11); the FFA4 agonist, Metabolex-36, at two doses: 6 mg·kg À1 (yellow bar with black horizontal stripes, n = 6) and 50 mg·kg À1 (yellow bar with black diagonal stripes, n = 10) compared with their vehicle control, 0.5% hydroxylpropyl methylcellulose (HPMC) + 0.1% Tween-80 (yellow bar, n = 10); the FFA1 agonist, TAK-875 (27 mg·kg
À1
, blue bar with white diagonal stripes, n = 11), compared with its vehicle control (0.5% methylcellulose, blue bar) and finally the FFA1 antagonist, ANT825 (29 mg·kg À1 , orange bar with white diagonal stripes, n = 7), compared with its vehicle [0.25% polyvinylpyrrolidone (PVP) + 0.05% SDS, orange bar, n = 7]. Each bar represents the mean+1SEM. Statistically significant differences from controls were *P < 0.05 (Student's t-test) . Differences between the oral doses of Metabolex-36 from its control and additionally between loperamide HCl (i.p.) and the FFA drugs were + P < 0.05 (one-way ANOVA with Dunnett's post hoc test).
FFA1 and FFA4 activities in mouse colon BJP mucosal responses were transient in comparison with Gα scoupled L cell signalling, for example, GPR119 or melanocortin-4 receptor (MC 4 receptor) (Cox et al., 2010; Panaro et al., 2014) .
FFA1 antagonism reveals FFA1 receptor-mediated mucosal and anti-motility tone and agonist-specificity
The FFA1 antagonists, ANT825 and GW1100 revealed, for the first time, a degree of endogenous FFA1 tone in colonic mucosa. The degree of tonic activity was similar to that observed with the MC 4 receptor antagonist, HS014 (3.6 μA·cm À2 ) (Panaro et al., 2014) . Since endogenous FFA1 and MC 4 receptor agonism stimulates PYY release from L cells, blockade of these receptors inhibits endogenous PYY release. Crivellato et al. (2002) demonstrated that enteroendocrine cells in mouse colon undergo piecemeal degranulation, hormone release that may be related to the tonic activity we observe in mucosa. Endogenous lipids, natural ligands of the FFA1 receptor (Itoh et al., 2003) may be responsible for the observed tonic activity via FFA1 receptor. The potency of the FFA1 competitive antagonist, ANT825 was not dissimilar from its potency (pEC 50 of 6.8) obtained in a human embryonic kidney 293 cell line expressing human FFA1 receptors, measuring inositol monophosphate (Waring et al., 2015) . We found GW1100 (pIC 50 of 5.99; Briscoe et al., 2006) abolished TUG424 responses but not TUG891 responses, showing FFA1 receptor selectivity as seen previously (Briscoe et al., 2006) . Like GW1100, ANT825 abolished FFA1 agonism but both FFA1 antagonists also partially inhibited GW9508 responses, indicating that at this concentration (1 μM), GW9508 exerts a dual agonism via FFA1 and most likely FFA4 receptors. Briscoe et al. (2006) revealed that GW1100 had no effect on the ability of GW9508 to activate FFA4 receptors. We conclude that GW9508 is a dual agonists attenuated colonic motility in vitro to a similar degree as seen previously with MC 4 receptor activation and GPR119 agonism (Panaro et al., 2014) . They decreased colonic motility presumably via the release of PYY, which mediates the colonic brake. Pretreatment with the FFA1 antagonist, GW1100, revealed basal colonic mucosal tone (as seen with Ussing chamber studies) indicative of endogenous FFA1 activity. In the presence of the FFA1 antagonist GW1100, the colonic brake induced by the FFA1 agonist (TUG424) was disinhibited and therefore, colonic transit increased, whereas transit induced by FFA4 agonist (TUG891) remained unaffected, showing selectivity of the FFA1 agonist.
As the FFA1 agonist, TAK875, and the FFA4 agonist, Metabolex-36, slowed transit in vitro, we investigated their ability to slow transit in vivo. Following the overnight fast, plasma glucose levels were reduced to 5 mmol l À1 . However, we established that FFA1 and FFA4 signalling is unchanged at 5 mM compared with 11.1 mM glucose as seen previously for GPR119 agonism (Patel et al., 2014) . Metabolex-36 slowed colonic transit significantly presumably via PYY, whereas TAK-875 failed to show significant inhibition of bead colonic transit when administered orally or via i.p. injection. This
Figure 7
The effect of an i.p. injection of loperamide HCl and FFA ligands on UGIT in vivo. The intestinal transit of a charcoal meal (expressed as a percentage of the small intestine length) after i.p. injection of the positive control, loperamide HCl (10 mg·kg À1 , red bar, n = 6), compared with its vehicle control, 0.5% methylcellulose (blue bar, n = 6); the FFA4 agonist, Metabolex-36 (50 mg·kg À1 , yellow bar with black diagonal stripes, n = 6), compared with its vehicle control, 0.5% hydroxylpropyl methylcellulose (HPMC) + 0.1% Tween-80 (yellow bar, n = 6); the FFA1 agonist, TAK875 (27 mg·kg À1 , blue bar with white diagonal stripes, n = 5), compared with its vehicle control (0.5% methylcellulose, blue bar) and the FFA1 antagonist, ANT825 (29 mg·kg À1 , orange bar with white diagonal stripes, n = 5), compared with its vehicle [0.25% polyvinylpyrrolidone (PVP) + 0.05% SDS, orange bar, n = 5]. Each bar represents the mean+1SEM. Statistically significant differences from controls were *P < 0.05 (Student's t-test), whereas differences between loperamide HCl and FFA drugs were + P < 0.05 (one-way ANOVA with Dunnett's post hoc test).
Figure 8
CYN 154806 had no effect on the Metabolex-36-induced increase in UGIT in vivo. The effect of Metabolex-36 (50 mg·kg À1 , i.p. injection) on UGIT in the absence (saline, n = 5) or presence (n = 5) of the SST 2 antagonist, CYN 154806. Bars represent mean+1SEM.
apparent lack of efficacy may be due to TAK-875's partial agonism or its administration as a suspension. In our in vitro transit studies, the isolated colon is severed from the central nervous system, and TAK-875 acts directly upon colonic FFA1 receptors. In the in vivo model, it is possible that the ability of TAK-875 to release PYY is not sufficient to alter colonic motility, with the added complication of modulatory CNS pathways. In addition, there are concerns in the literature that isoflurane interferes with GI transit. In 2005, Torjman and colleagues reported that 6 min exposure to isoflurane in rats slows UGIT by 50% (Torjman et al., 2005) . In our study, mice received a 2 min exposure of isoflurane 1 h after the drug, vehicle or positive control was administered, followed by bead insertion and excretion. Therefore, we conclude that this brief exposure of isoflurane in our protocol (at the time of maximal drug exposure) should have minimal effect on colonic motility. Furthermore, we note that there are no differences in colonic transit rates between different vehicle controls (oral gavage vs. i.p.) in this study, compared with those in a previous investigation (Forbes et al., 2012) . Unexpectedly, Metabolex-36 was pro-motile in the upper intestine. The FFA4 receptor is expressed on I cells, K cells and L cells causing release of CCK, GIP and PYY (and GLP-1) respectively, via Gα q signalling (Hirasawa et al., 2005; Tanaka et al., 2008; Iwasaki et al., 2015) . These peptides inhibit gastric emptying and small intestinal transit and additionally, PYY is responsible for both ileal and colonic brakes (Spiller et al., 1984; Spiller et al., 1988) . However, recently the FFA4 receptor has been identified in gastric ghrelin and somatostatin cells, signalling via Gα i proteins to inhibit peptide release (Engelstoft et al., 2013; Egerod et al., 2015) . Somatostatin is known to inhibit motility and increase the interval between migrating myoelectric complexes, therefore slowing transit. We hypothesized that Metabolex-36 increased intestinal motility by inhibiting somatostatin release and tested this possibility with the SST 2 antagonist, CYN 154806, at an effective dose used previously in rat small intestine, in vivo (Booth et al., 2001) . However, CYN 154806 was ineffective (at 3 mg·kg À1 ), and we conclude that either the antagonist dose used was too low in the mouse or Metabolex-36 produces a promotile effect via an alternative FFA4 mechanism.
PYY-Y 1 but not PYY-Y 2 mediation of FFA1 and FFA4 receptor signalling in mouse colonic mucosa FFA1 and FFA4 agonist responses in the mouse colon were Y 1 receptor mediated. Additionally, these responses were unaffected by TTX indicating a predominantly epithelial origin for FFA1 and FFA4 agonism, not involving TTX-sensitive submucosal neurons. The degree of antisecretory tone mediated by the Y 1 and Y 2 receptors was similar to that shown previously in mouse colon (Hyland et al., 2003; Tough et al., 2011) . The FFA1 and FFA4 receptor signalling in colonic mucosa are mediated by endogenous PYY acting on localepithelial Y 1 receptors. This Y 1 receptor mechanism and the lack of any Y 2 receptor (neuronal) involvement is consistent with our previous findings for other L cell-enriched receptors, for example, MC 4 (Panaro et al., 2014), GPR119 (Patel et al., 2014) , FFA2 receptors (Forbes et al., 2015) and the calciumsensing receptor (Joshi et al., 2013) . In addition, there appears to be no GLP-1 mediation of FFA1 and FFA4 responses in this study. GLP-1 has a half-life of 1.5 min which limits the ability to detect its response, if any. Furthermore, we have discovered that the GLP-1 response can vary along the colon, with larger GLP-1 responses observed in the ascending colon and smallest in the descending colon (Tough et al., 2017) . Here, we used the descending colon, and in combination with the short half-life of GLP-1, this may explain why we did not see a GLP-1-mediated electrogenic response.
FFA1 and FFA4 receptor-mediated responses in mouse colon mucosa are glucose sensitive
Our studies demonstrate for the first time that activation of FFA1 and FFA4 receptor-mediated responses in native tissues are glucose sensitive as seen in previous investigations of L cell-specific activation by GPR119 (Cox et al., 2010) , MC 4 receptor (Panaro et al., 2014) , the activation of the calciumsensing receptor by L-glutamine (Joshi et al., 2013) and FFA2 agonism (Forbes et al., 2015) . Theoretically, these agonists should not therefore cause hypoglycaemia in vivo, a disadvantage of certain anti-diabetic drugs currently on the market. FFA1 and FFA4 receptors are currently clinically favourable targets as they are not only co-expressed in GI L cells but differentially expressed in the pancreas. The FFA1 receptor is expressed in pancreatic β cells (Itoh et al., 2003) , and the FFA4 receptor has recently been discovered in somatostatin-containing delta cells (Stone et al., 2014) . PYY and GLP-1 released from the L cells should enhance satiety (an advantage for patients with associated obesity) and elevate insulin release respectively via activation of GLP-1 receptors on pancreatic β cells. Furthermore, an FFA1 agonist could simultaneously directly elevate insulin release after a meal. This combination of indirect and direct FFA1 receptor-mediated effects should improve glucose tolerance without hypoglycaemia.
Final conclusions
We have shown that selective FFA1 and FFA4 agonism is PYY Y 1 receptor-mediated and glucose-sensitive in mouse descending colon mucosa. These selective agonists would limit potential hypoglycaemia, a side effect of certain commercially available anti-diabetic drugs. ANT825 and GW1100 revealed tonic FFA1 receptor-mediated activity and the possibility of FFA1 endogenous ligands causing PYY release. Furthermore, we have shown for the first time that agonism of FFA1 and FFA4 receptors inhibits colonic transit in vitro and FFA4 agonism induces regional differences in transit in vivo. In colonic L cells, agonism of the FFA4 receptor is presumably Gα q -mediated and leads to antisecretory mucosal responses and retarded colonic transit, but FFA4 agonism leads to upper GI pro-motile activity in vivo in the mouse, which remains unresolved. FFA1 and FFA4 coagonism may be beneficial therapeutically and would more closely mimic the combinatorial activity of long chain fatty acids in the diet. 
